Astellas Pauses Dosing of AT132 in ASPIRO Clinical Trial for the Treatment of X-linked Myotubular Myopathy
Shots: Astellas discontinue the dosing in the ASPIRO trial that evaluates AT132 in 24 participants (7 at the 1.3×1014 vg/kg dose and 17 at the 3.5×1014 vg/kg dose) with XLMTM. The participant has a history of intermittent cholestasis The discontinuation is due to serious AEs in a study that demonstrated abnormal LFTs in patients who […]